Next-generation antibody-drug conjugate designs aim to push the envelope even further. Antibody–drug conjugates (ADCs) are among the fastest growing therapeutic modalities in modern cancer drug ...

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal ...